Patents Assigned to Pfizer
-
Publication number: 20240173293Abstract: The present disclosure provides methods of treating breast cancer with a combination of amcenestrant and palbociclib.Type: ApplicationFiled: March 2, 2022Publication date: May 30, 2024Applicants: Sanofi, Pfizer Inc.Inventors: Marina CELANOVIC, Gautier PAUX, Justin Thomas HOFFMAN, Sandrine ANNEHEIM, Sylvaine CARTOT-COTTON, Patrick COHEN, Alice GOSSELIN
-
Publication number: 20240173332Abstract: Pharmacuetical Compounds Benzodiazepine derivatives of formula (I): wherein: R1 is H or F; R2 is selected from formula (II) and formula (III) R3 is C1-C6 alkyl which is unsubstituted or substituted by CF3, or is a monocyclic 4- to 6-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N and S; R4 is H or a group selected from —X, -alk-X, —CONR6R7, C?NNR6R7, —SO2R6 and —SO2NR6R7; R4 is a group selected from —X, -alk-X, —CONR6R7, —C?NNR6R7, —SO2R6 and —SO2R6R7; X is OH or a derivative of an OH group selected from ?-amino carboxylic acid esters, carboxylic acid esters, carbonates, carbamates, ethers and phosphates: alk is C1-C6 alkylene which is unsubstituted or substituted by C3-C6 cycloalkyl; and R6 and R7 are each independently C1-C6 alkyl or C3-C6 cycloalkyl; and the pharmaceutically acceptable salts thereof are inhibitors of respiratory syncytial virus (RSV) and can therefore be used to treat or prevent an RSV infection.Type: ApplicationFiled: February 24, 2022Publication date: May 30, 2024Applicant: Pfizer Inc.Inventors: Matthew Barrett, Alexandre Bedernjak, George Stuart Cockerill, James Good
-
Patent number: 11993625Abstract: The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.Type: GrantFiled: January 10, 2018Date of Patent: May 28, 2024Assignee: Pfizer, Inc.Inventors: Omar Khaled Ahmad, Stephen Paul Brown, Kenneth John Dirico, Russell Dushin, Gary Frederick Filzen, Sujiet Puthenveetil, Pavel Strop, Chakrapani Subramanyam, Lawrence N. Tumey
-
Publication number: 20240166710Abstract: The subject matter described herein is directed to methods of treating growth hormone related disorders by administering a long-acting recombinant human growth hormone. In another embodiment, a long-acting recombinant human growth hormone is administered in a composition or the combination is administered separately to treat growth deficiency in a subject previously treated with a once daily rhGH therapy.Type: ApplicationFiled: March 17, 2022Publication date: May 23, 2024Applicants: Pfizer Inc., OPKO Biologics Ltd.Inventors: Jóse Francisco Cara, Aleksandra Pastrak, Srinivas Rao Valluri, Michael Paul Wajnrajch
-
Patent number: 11987634Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.Type: GrantFiled: June 1, 2022Date of Patent: May 21, 2024Assignee: PFIZER INC.Inventors: Siler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
-
Publication number: 20240158473Abstract: Antibody compositions and methods for the purification of antibodies are provided. Purification methods provided involve the use of hydroxyapatite resin (HA) to separate an antibody of interest from one or more impurities.Type: ApplicationFiled: December 21, 2023Publication date: May 16, 2024Applicant: PFIZER INC.Inventors: Timothy ISKRA, Ashley Margaret SACRAMO
-
Publication number: 20240156822Abstract: Method for treating vitiligo, including active and stable non-segmental vitiligo, using compounds and analogues which inhibit certain kinases including Janus Kinase (JAK), said method comprising the step of administering to the subject in need thereof 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 28, 2022Publication date: May 16, 2024Applicant: Pfizer Inc.Inventor: Elena Peeva
-
Publication number: 20240156819Abstract: The present invention relates to an oral solution formulation or an oral powder for constitution comprising 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazirt-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, or a lactate or malate salt thereof, and a buffer system comprising lactic acid or malic acid.Type: ApplicationFiled: January 23, 2024Publication date: May 16, 2024Applicant: Pfizer Inc.Inventors: Ashwinkumar Jain, Weili Yu
-
Publication number: 20240156977Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.Type: ApplicationFiled: October 23, 2023Publication date: May 16, 2024Applicant: Pfizer Inc.Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
-
Patent number: 11980669Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.Type: GrantFiled: March 3, 2020Date of Patent: May 14, 2024Assignee: Pfizer, Inc.Inventors: Xiaotian Zhong, Amarnauth Shastrie Prashad, Ronald William Kriz, Tao He, Will Somers, Wenge Wang, Leo Joseph Letendre
-
Patent number: 11981696Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O?M+), —P(O)(O?M+)2 and —P(O)(O?)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.Type: GrantFiled: March 14, 2019Date of Patent: May 14, 2024Assignee: Pfizer Inc.Inventors: Tamim Fehme Braish, Matthew Frank Brown, Ye Che, Richard Andrew Ewin, Timothy Allan Johnson, Michael Joseph Melnick, Justin Ian Montgomery, Mark Stephen Plummer, Loren Michael Price, Usa Reilly, Daniel Uccello
-
Publication number: 20240150394Abstract: Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.Type: ApplicationFiled: May 23, 2023Publication date: May 9, 2024Applicant: PFIZER INC.Inventors: Durgesh V. Nadkarni, Jeffry R. Borgmeyer, He Meng, Qingping Jiang
-
Publication number: 20240150334Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD and NASH.Type: ApplicationFiled: October 6, 2023Publication date: May 9, 2024Applicant: Pfizer Inc.Inventors: Jan Antoinette Cusi Romero Adams, Bruce Michael Bechle, Jason Kenneth Dutra, Michelle Renee Garnsey, Xinjun Hou, Jisun Lee, Deane Milford Nason, II, Steven Victor O'Neil, Danica Antonia Rankic, Yang Wang, Ann Sorrentino Wright, Lei Zhang, Liying Zhang, David James Edmonds
-
Patent number: 11976064Abstract: The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.Type: GrantFiled: May 6, 2022Date of Patent: May 7, 2024Assignee: Pfizer Inc.Inventors: Omar Ahmad, Andrew Fensome, Erik Alphie LaChapelle, Ethan Lawrence Fisher, Rayomand J. Unwalla, Jun Xiao, Lei Zhang
-
Publication number: 20240140937Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: ApplicationFiled: November 28, 2023Publication date: May 2, 2024Applicant: Pfizer Inc.Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
-
Publication number: 20240140947Abstract: The invention relates to 4-((6-(2,2-Difluoroethyl)-8-(2-hydroxy-2-methylcyclopentyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)piperidine-1-sulfonamide or pharmaceutically acceptable salts thereof, to compositions containing them, to processes for their preparation, to intermediates used in such processes, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer. The disclosure also relates to its crystalline form 1, to pharmaceutical compositions comprising form 1, and to the use of form 1 for the treatment of cancers.Type: ApplicationFiled: October 17, 2023Publication date: May 2, 2024Applicant: Pfizer Inc.Inventors: Fengjuan Cao, Kevin Daniel Freeman-Cook, Rhys Marsden Jones, Scott Channing Sutton
-
Patent number: 11970524Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.Type: GrantFiled: December 17, 2020Date of Patent: April 30, 2024Assignees: PFIZER INC., BOSTON MEDICAL CENTER CORPORATIONInventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
-
Publication number: 20240132483Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.Type: ApplicationFiled: November 20, 2023Publication date: April 25, 2024Applicant: Pfizer Inc.Inventors: Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, John M. Curto, David J. Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
-
Publication number: 20240132477Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.Type: ApplicationFiled: December 13, 2021Publication date: April 25, 2024Applicant: Pfizer Inc.Inventors: Scott William Bagley, Agustin Casimiro Garcia, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
-
Patent number: 11964978Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.Type: GrantFiled: March 11, 2022Date of Patent: April 23, 2024Assignee: PFIZER INC.Inventors: Ketan Satish Gajiwala, Chan Woo Huh, Mehran Jalaie, Ryan Lloyd Patman, Eugene Yuanjin Rui, Jianmin Sun, Martin James Wythes